Protein Summary
Involved in autophagic vesicle formation. Conjugation with ATG12, through a ubiquitin-like conjugating system involving ATG7 as an E1-like activating enzyme and ATG10 as an E2-like conjugating enzyme, is essential for its function. The ATG12-ATG5 conjugate acts as an E3-like enzyme which is required for lipidation of ATG8 family proteins and their association to the vesicle membranes. Involved in mitochondrial quality control after oxidative damage, and in subsequent cellular longevity. Plays a critical role in multiple aspects of lymphocyte development and is essential for both B and T lymphocyte survival and proliferation. Required for optimal processing and presentation of antigens for MHC II. Involved in the maintenance of axon morphology and membrane structures, as well as in normal adipocyte differentiation. Promotes primary ciliogenesis through removal of OFD1 from centriolar satellites and degradation of IFT20 via the autophagic pathway. May play an important role in the apopto ...more
- ENST00000343245
- ENSP00000343313
- ENSG00000057663
- ENST00000369076
- ENSP00000358072
- ENST00000635758
- ENSP00000490493
- APG5L
- ASP
- ASP
- APG5
- APG5L
- hAPG5
- SCAR25
- APG5-LIKE
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 1 | ||
biological process | 0.99 | ||
kinase perturbation | 0.99 | ||
transcription factor perturbation | 0.94 | ||
transcription factor binding site profile | 0.89 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1471.1 (req: < 5)
Gene RIFs: 161 (req: <= 3)
Antibodies: 884 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1471.1 (req: >= 5)
Gene RIFs: 161 (req: > 3)
Antibodies: 884 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 33
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0